Genetics & Genomics

Breast Cancer Risk Associated With CHEK2 Mutations

genetic analysis, mutations, hereditary risk
ONF 2014, 41(6), 692-694. DOI: 10.1188/14.ONF.692-694

Most efforts to identify individuals who have a hereditary predisposition for developing breast cancer had focused on the BRCA1 and BRCA2 genes. Less common susceptibility genes also are associated with increased risk for developing breast cancer, but until recently have often gone undetected. With the advent of next generation sequencing (NGS), many families with suspected hereditary risk are undergoing testing for multiple genes associated with increased cancer risk (Mahon, 2013a). One gene that is commonly included on NGS hereditary breast cancer panels is CHEK2. Increasingly, oncology nurses will encounter patients and families affected with mutations on this gene and need to understand the implications it has for screening and treatment.

Jump to a section


    Apostolou, P., & Fostira, F. (2013). Hereditary breast cancer: The era of new susceptibility genes. Retrieved from
    Bodmer, W., & Tomlinson, I. (2010). Rare genetic variants and the risk of cancer. Current Opinion in Genetics and Development, 20, 262-267.
    Cybulski, C., Wokolorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., … Lubinski, J. (2011). Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. Journal of Clinical Oncology, 29, 3747-3752. doi:10.1200/JCO.2010.34.0778
    Gage, M., Wattendorf, D., & Henry, L. R. (2012). Translational advances regarding hereditary breast cancer syndromes. Journal of Surgical Oncology, 105, 444-451.
    Hollestelle, A., Wasielewski, M., Martens, J. W. M., & Schutte, M. (2010). Discovering moderate-risk breast cancer susceptibility genes. Current Opinion in Genetics and Development, 20, 268-276.
    Lalloo, F., & Evans, D. G. (2012). Familial breast cancer. Clinical Genetics, 82, 105-114. doi:10.1111/j.1399-0004.2012.01859.x
    Mahon, S. (2013a). Next-generation DNA sequencing: Implications for oncology care. Oncology Nursing Forum, 40, 437-439. doi:10.1188/13.ONF.437-439
    Mahon, S. (2013b). Ordering the correct genetic test: Implications for oncology and primary care healthcare professionals. Clinical Journal of Oncology Nursing, 17, 128-131.
    Márquez-Rodas, I., Solís, R. M., Cobo, S. L. T., & Martín, M. (2012). Hereditary breast cancer: From genetics To clinical management. European Journal of Clinical and Medical Oncology, 4, 39-47.
    Maxwell, K. N., & Nathanson, K. L. (2013). Common breast cancer risk variants in the post-COGS era: A comprehensive review. Breast Cancer Research, 15, 212.
    Narod, S. A. (2010). Testing for CHEK2 in the cancer genetics clinic: Ready for prime time? Clinical Genetics, 78, 1-7.
    Shannon, K. M., & Chittenden, A. (2012). Genetic testing by cancer site: Breast. Cancer Journal, 18, 310-319. doi:10.1097/PPO.0b013e318260946f
    Tung, N., & Silver, D. P. (2011). Chek2 DNA damage response pathway and inherited breast cancer risk. Journal of Clinical Oncology, 29, 3813-3815. doi:10.1200/JCO.2011.37.1476